Jonathan Medved
CEO @ OurCrowd
Jerusalem, Israel
Jonathan Medved is a Series A investor at OurCrowd in Jerusalem focused on Software and Biotechnology. Jonathan Medved is based out of Jerusalem, Yerushalayim and is the Founder and Chairman of the board of OurCrowd. Jonathan previously worked at Israel Seed Partners as a Founder and General Partner. Jonathan Medved attended the University of California Berkeley.
- Total investments:
- 27
- Last investment:
- Lead investor:
- 41%
Last updated:
For AI agents: llms.txt
Industries Jonathan Medved invests in
Stages Jonathan Medved invests in
Countries Jonathan Medved invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Software 6 (22%)
- Biotechnology 6 (22%)
- Health Care 5 (19%)
- Analytics 4 (15%)
- Information Technology 4 (15%)
Stage
- Series A 7 (26%)
- Series B 7 (26%)
- Seed 6 (22%)
- Venture - Series Unknown 3 (11%)
- Series C 1 (4%)
Country
- Israel 13 (48%)
- United States 8 (30%)
- Canada 2 (7%)
- New Zealand 1 (4%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| CytoReason is a tech company developing a computational model of the human body. The company collects proprietary data from pharma companies and uses it to simulate human diseases – tissue by tissue, cell by cell. With CytoReason’s massive database and AI-led platform, pharma and biotech companies identify new opportunities, shorten trial phases,reduce development costs and increase the likelihood of approval. To date, six of the world’s top ten pharma companies use CytoReason’s technology. | $80M / Series B / Jul 17, 2024 | ||
| Carrar manufactures and designs a wide range of thermal management technology systems for the electric mobility industry. | $5.3M / Series A / Apr 09, 2024 | ||
| Cyabra enables global enterprises and governments to understand and respond to online manipulation that distorts public perception and decision-making. As manipulated content, coordinated behaviors, and inauthentic actors increasingly shape what people see and believe online, organizations need clarity about what is real, what is coordinated, andwhat actually matters. Cyabra analyzes three foundational elements of information integrity: actors, behaviors, and content. By examining who is operating, how activity is coordinated and amplified, and how narratives are leveraged, Cyabra helps organizations distinguish isolated noise from coordinated influence. Operating at scale, Cyabra enables teams to focus on the small number of actors and behaviors responsible for disproportionate impact. Evidence is translated into clear mitigation steps that fit directly into existing workflows, allowing organizations to act proportionately, avoid unnecessary escalation, and reduce misdirected response. Cyabra supports continuous analysis across evolving situations, allowing organizations to move fluidly between broad patterns and specific cases without losing context. This combination of scale, precision, and usability turns overwhelming information into practical clarity. Today, Cyabra is used by leading global enterprises, communications firms, and public-sector organizations. The solution maintains a neutral, evidence-led posture and is designed for situations where judgment, credibility, and clarity are essential. | $5.7M / Series A / Jan 11, 2024 | ||
| Mermade Seafoods is a pioneering cellular aquaculture company, bringing a novel approach and mindset for the production of cell based seafood. Our approach enables mass production of cultured seafood using a sustainable and recyclable fermentation-based process that results in clean, healthy, and sustainable protein-rich seafood products, bringingfood security for future generations.Technology:Mermade Seafoods aims to be the first company to provide a circular method of production that will revolutionize the cell-based fermentation industry by using side-stream valorisation of growth media. The company's ground breaking technology is based on upcycling biological waste products from spent growth media and turn it into new, nutrient-rich food for the growing cells. This transformative technology enables the resolution of the biggest challenges the cell-based industry is facing - high production costs, and waste accumulation. Mermade Seafoods's™ technology is based on a well-known practice in conventional aquaculture known as aquaponics, adapted to the cellular level to spearhead the next revolution of cellular agriculture by creating a new agrotech field of Cytoponics. | $3.3M / Seed / Aug 29, 2022 | ||
| SaNOtize is a biotech company using a platform technology for topical to treat upper respiratory and dermal infections. The company develops a Nitric Oxide Releasing Solution platform technology to treat and prevent microbial infections, including drug resistant microbes. Its target indications include treatment for strep throat, athlete'sfoot, infected wounds, diabetic foot ulcers, sinusitis, cold and flu, and others.SaNOtize was founded in 2017 by Gilly Regev and Chris Miller and it is headquartered in Vancouver, British Columbia. | $24M / Series B / Aug 24, 2022 | ||
| Sotero provides a data protection platform offering field-level encryption for data in use, data at rest, and data in motion across on-premise and cloud data stores. The company utilizes sophisticated encryption for data in use, including deterministic, random and format-preserving encryption and is also compatible with all on-prem, cloud andhybrid data stores, including Oracle, SQL Server, MySQL, Hadoop, Avalanche, Snowflake, Yellowbrick, Postgres, and MongoDB, and comes with pre-built integrations to leading access and key management solutions. | $8M / Seed / Jul 20, 2022 | ||
| MAOLAC is a producer of nutrition products. Their functional milk proteins offer humans and animals immune protection that includes sports nutrition, healthy aging, leaky gut, gut health, relief of joint pain, and reduction of skin infections. | $3.2M / Seed / Jul 05, 2022 | ||
| BioLumic develops light signals that activate plant growth and unlock the natural genetic potential of crops. The company's photogenics platform leverages innovation in plant science, light technology and genetic insights. Demonstrated results include higher yield, improved vigor, increased disease and pest resistance, and improvements incrops composition. These results have been across a variety of seeds and seedling: soybean, cannabis and vegetable and fruit crops. It is a clean technology that does not require the use of chemicals or amendments. BioLumic is a private company and was founded in 2013. | $13.5M / Series B / Jun 21, 2022 | ||
| Indoor Positioning, without the hassle (no beacons, no WiFi). Oriient offers hyper-accurate Indoor Positioning to any app, in any building, anywhere. All this, without installing anything in the building. We power smart retail, smart buildings, IoT and AR applications. | $11M / Series A / May 10, 2022 | ||
| Sequentify provides a technology that is based on tools from the synthetic biology and AI software worlds for targeted DNA sequencing applications such as cancer diagnostics, carrier screening, COVID-19 surveillance and other applications. | $7M / Seed / May 10, 2022 | ||
| See all 27 investments → | |||
Co-Investors
About OurCrowd
OurCrowd is a venture investing platform that enables institutions and individuals to invest and engage in emerging companies. OurCrowd was started in 2013, driven by the idea that the business of building startups grows bigger and better when the global 'crowd' gains access to VC-level investment opportunities.
OurCrowd Contacts
| Name | Phone | Socials | |
|---|---|---|---|
David Shore
Vice President, Investor Relations - Canada
|
|||
Denes Ban
Managing Director, Partner
|
|||
Etai Kramer
Managing Director, Head Funds
|
|||
Lenny Roth
Partner
|
|||
Steven Blumgart
Chairman
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Jonathan Medved invest in?
Jonathan Medved invests primarily in Software, Biotechnology and Health Care startups, most often at Series A and Series B stage. Most of the 27 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Jonathan Medved?
Public channels for Jonathan Medved include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Jonathan Medved last invest?
The most recent investment recorded for Jonathan Medved closed in Jul 2024. Shizune tracks 27 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
